CoChat
Sign Up
Cited by 84Hormonal and reproductive studiesProstate Cancer Treatment and ResearchMenopause: Health Impacts and Treatments

Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation

Open access
Thompson, Carrie A., Shanafelt, Tait D., Loprinzi, Charles L.·2003·The Oncologist
DOI 10.1634/theoncologist.8-5-474
Open this paper in CoChat — free accountOpen PDF

Abstract

Learning Objectives: After completing this course, the reader will be able to: Explain the side effects of hormonal ablation therapy for prostate cancer. Provide a list of potential non-hormonal therapies for treatment of vasomotor symptoms. Appreciate the impact of hormonal ablation therapy on bone mineral density. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com Andropause, or the age-related decline in serum testosterone, has become a popular topic in the medical literature over the past several years. Andropause includes a constellation of symptoms related to lack of androgens, including diminished libido, decreased generalized feeling of well-being, osteoporosis, and a host of other symptoms. The andropause syndrome is very prominent in men undergoing hormonal ablation therapy for prostate cancer. Most significant in this population are the side effects of hot flashes, anemia, gynecomastia, depression, cognitive decline, sarcopenia, a decreased overall quality of life, sexual dysfunction, and osteoporosis with subsequent bone fractures. The concept of andropause in prostate cancer patients is poorly represented in the literature. In this article, we review the current literature on the symptoms, signs, and possible therapies available to men who cannot take replacement testosterone.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.8-5-474

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Hormonal therapy side effects include hot flashes, osteoporosis, anemia, fatigue, sarcopenia, gynecomastia, loss of libido, erectile dysfunction, diabetes risk, cardiovascular disease risk, fatal cardiac events, and possible emotional distress.

    “These side effects include: hot flashes, osteoporosis, anemia, fatigue, sarcopenia, gynecomastia, loss of libido, erectile dysfunction, risk of diabetes, risk of cardiovascular disease and fatal cardiac events as well as possible emotional distress [9–13].”

    From Prostate cancer: Psychosocial implications and management (2008) · cites this paper as [11]

    The Andropause and Prostate Cancer, Sarcopenia, and Sexual Dysfunction sections support most of the listed effects of hormonal ablation, including hot flashes, osteoporosis, anemia, fatigue, muscle loss, gynecomastia, reduced sexual desire, erectile difficulties, and depression. The Osteoporosis and Vasomotor Symptoms sections associate cardiovascular effects specifically with estrogen therapy; the cited paper does not establish diabetes risk or fatal cardiac events as side effects of hormonal ablation generally. Page numbers were not supplied in our copy. (LLM, conf=0.89)

    Experimental — accuracy not yet measured

  • Androgen ablation therapy also affects cognitive functioning.

    “Recently, review articles discussing the side effects of androgen ablation therapy have stated that this treatment also impacts cognitive functioning [9, 11].”

    From Prostate cancer: Psychosocial implications and management (2008) · cites this paper as [11]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

4 of the 149 references couldn’t be matched to a known paper.

Research works printed but not linked: 13

  1. [2]2. van den Beld AW, Lamberts SW. The male climacterium: clin- ical signs and symptoms of a changing endocrine environment. Prostate Suppl 2000;10:2-8.
  2. [17]17. Huggins C, Stevens RE, Hodges CV. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209.
  3. [42]42. Roth AJ, Scher HI. Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psychooncology 1998;7:129-132.
  4. [48]48. Bales GT, Sinner MD, Kim JH et al. Impact of intermittent androgen deprivation on quality of life (QOL). Proc Am Urol Assoc 1996;155:1069.
  5. [61]61. Townsend MF, Sanders WH, Northway RO et al. Bone frac- tures associated with luteinizing hormone-releasing hor- mone agonists used in the treatment of prostate carcinoma. Cancer 1997;79:545-550.
  6. [70]70. Diamond T, Campbell J, Bryant C et al. The effect of com- bined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998;83:1561-1566.
  7. [71]71. Smith MR, McGovern FJ, Fallon MA et al. Low bone min- eral density in hormone-naïve men with prostate carcinoma. Cancer 2001;91:2238-2245.
  8. [72]72. Higano C, Stephens C, Nelson P et al. Prospective serial mea- surements of bone mineral density in prostate cancer patients without bone metastases treated with intermittent androgen suppression. Proc Am Soc Clin Oncol 1999;18:314A.
  9. [77]77. Diamond TH, Winters J, Smith A et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate car- cinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001;92:1444-1450.
  10. [86]86. Fonseca R, Rajkumar SV, White WL et al. Anemia after orchiectomy. Am J Hematol 1998;59:230-233.
  11. [93]93. Silberstein PT, Witzig TE, Sloan JA et al. Weekly erythropoi- etin for patients with chemotherapy induced anemia: a random- ized, placebo-controlled trial in the North Central Cancer Treatment Group. Proc Am Soc Clin Oncol 2002;21:356a.
  12. [95]95. Morley JE, Baumgartner RN, Roubenoff R et al. Sarcopenia. J Lab Clin Med 2001;137:231-243.
  13. [137]137. Klotz LH, Herr HW, Morse MJ et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;58:2546- 2550. 140

Cited by

Sorted by citations

Related

Authors
Thompson, C. A., Shanafelt, T. D., & Loprinzi, C. L.
Affiliations
Mayo Clinic (US)
Corresponding author
Loprinzi, Charles L.
ORCID
Venue
The Oncologist
Publisher
Oxford University Press (OUP)
Published
2003-10-01
Volume
8
Issue
5
Pages
474-487
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
DOI
10.1634/theoncologist.8-5-474
OpenAlex
W2127687909
Cited by
84
References
149
Citations by year
2026: 2 · 2022: 1 · 2020: 1 · 2019: 2 · 2017: 3 · 2015: 4 · 2014: 4 · 2013: 2 · 2012: 14
FWCI
0.85
Type
journal article
Language
en
Open access
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations
  • The Oncologist (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
andropause, prostate cancer, androgen deficiency, vasomotor symptoms, hot flashes, bone mineral density, osteoporosis, sexual dysfunction, gynecomastia, anemia, depression, sarcopenia, quality of life, symptom management
MeSH terms
Climacteric, Estradiol, Humans, Male, Prostatic Neoplasms, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review